What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

PTSD Clinical Trials 2026: MDMA-Assisted Therapy, Stellate Ganglion Block & New Treatments

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Post-traumatic stress disorder affects approximately 20 million people in the US alone, with particularly high rates among veterans, first responders, and survivors of assault. Current treatments — SSRIs and trauma-focused psychotherapy — help many but leave a substantial proportion with persistent symptoms. In 2026, PTSD research is advancing rapidly, particularly with MDMA-assisted therapy nearing FDA approval, and novel approaches including stellate ganglion block and psychedelic-assisted therapy gaining evidence.

MDMA-Assisted Therapy

MDMA-assisted psychotherapy combines 2–3 extended therapy sessions (8 hours each) with MDMA administration, plus preparatory and integration sessions. Phase 3 trials (MAPP1 and MAPP2) showed 67–71% of participants no longer met PTSD diagnostic criteria at follow-up, compared to 32% in placebo+therapy groups.

Despite compelling efficacy data, the FDA did not approve MDMA-AT in August 2024, citing concerns about trial design and requesting an additional Phase 3 trial. Lykos Therapeutics (formerly MAPS PBC) is conducting the MAPP3 trial, actively recruiting. Participants receive MDMA or placebo during structured therapy sessions in an inpatient setting with two trained therapists present throughout each session.

Stellate Ganglion Block

Stellate ganglion block (SGB) is a nerve block procedure injecting local anesthetic near a cluster of sympathetic nerves in the neck. Originally used for hot flashes and pain, military physicians noticed incidental PTSD improvement. The ESTEEM trial (Walter Reed) showed significant PTSD symptom reduction with a single injection. Phase 3 trials with more rigorous designs are now recruiting, particularly targeting military populations. The procedure takes about 30 minutes and can be performed in outpatient settings.

Psilocybin and Other Psychedelic-Assisted Approaches

Following the depression research model, psilocybin-assisted therapy for PTSD is entering Phase 2 trials. MAPS and several academic centers are also investigating ibogaine for treatment-resistant PTSD — a Phase 2 trial in veterans at Stanford showed dramatic symptom reduction at one-month follow-up with a single dose. Ibogaine carries cardiac risks (QT prolongation) and requires careful screening.

Novel Pharmacotherapies

Prazosin (an alpha-1 blocker) has been studied for PTSD nightmares — a VA-funded Phase 3 trial (TRACTS) showed benefit in the veteran population. Brexanolone (IV neurosteroid) and zuranolone (oral neurosteroid) are in early PTSD trials. Oxytocin as an augmentation strategy to enhance psychotherapy outcomes is in multiple Phase 2 trials.

Veteran-Specific Resources

Veterans with PTSD have access to VA-funded trials through the VA Research program (research.va.gov). The VA's National PTSD Center maintains a trial database at ptsd.va.gov. The Cohen Veterans Network and Give an Hour also connect veterans to research opportunities. For non-veterans, ClinicalTrials.gov searches for "PTSD" with status "Recruiting" return over 200 active studies globally.